Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: MYADM

Summary for MYADM

Gene information	Gene symbol	MYADM
	Ensembl ID	ENSG00000179820
	Entrez ID	91663
	Gene name	myeloid associated differentiation marker
	Synonyms	NA
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: MYADM

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.337073	3.43e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.296082	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.579031	7.71e-20
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.276467	3.30e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	-0.332225	6.66e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.869529	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.570714	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.517546	1.07e-10
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.271111	7.66e-05
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.342749	5.00e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.760497	4.97e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.259875	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.400585	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.319816	1.03e-08
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.264505	4.92e-25
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.356047	1.38e-16
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.61199	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.45472	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	cDCs	0.27147	9.60e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.817641	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.428704	7.17e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.315282	4.66e-06
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.266205	1.01e-29
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.369334	8.10e-08
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.16895	1.46e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.339142	1.10e-08
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.265346	1.50e-09
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.606679	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.610233	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.561988	2.35e-27
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.394363	3.71e-25
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.279367	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.588993	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.542312	1.39e-12
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.422391	1.96e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.886387	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.316475	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.253474	2.24e-27
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.978025	0.00e+00

Top

Expression of MYADM in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MYADM

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating MYADM

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
MYADM	hsa-miR-5011-5p	100	NM_001290189
MYADM	hsa-miR-190a-3p	100	NM_001290189
MYADM	hsa-miR-8485	99.8514	NM_001290189
MYADM	hsa-miR-5196-5p	96.1595	NM_001290189
MYADM	hsa-miR-4747-5p	96.1595	NM_001290189
MYADM	hsa-miR-6859-5p	95.6114	NM_001290189
MYADM	hsa-miR-3916	95.6114	NM_001290189
MYADM	hsa-miR-3125	95.6114	NM_001290189
MYADM	hsa-miR-4533	94.5412	NM_001020818
MYADM	hsa-miR-1277-5p	93.067	NM_001290189
MYADM	hsa-miR-4692	91.8602	NM_001290189
MYADM	hsa-miR-4514	91.8602	NM_001290189
MYADM	hsa-miR-3145-3p	89.6779	NM_001290189
MYADM	hsa-miR-3065-3p	89.0079	NM_001020818
MYADM	hsa-miR-4306	86.8437	NM_001290189
MYADM	hsa-miR-4728-5p	86.3909	NM_001290189
MYADM	hsa-miR-506-3p	85.5485	NM_001020818
MYADM	hsa-miR-124-3p	85.5485	NM_001020818
MYADM	hsa-miR-4729	84.3053	NM_001290189
MYADM	hsa-miR-6785-5p	83.9825	NM_001290189
MYADM	hsa-miR-570-3p	80.2784	NM_001290189

Page: 1

Top

Motifs and transcription factors (TFs) regulating MYADM

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
MYADM	dbtfbs__ZSCAN16_HEK293_ENCSR864VJE_merged_N1	ZSCAN16 (directAnnotation).
MYADM	metacluster_130.2	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).
MYADM	transfac_pro__M05521	ZNF398 (directAnnotation).
MYADM	transfac_pro__M06754	ZBTB39 (directAnnotation).
MYADM	transfac_pro__M05671	ZNF25 (directAnnotation).
MYADM	transfac_pro__M06028	ZNF749 (directAnnotation).
MYADM	transfac_pro__M06700	ZNF71 (directAnnotation).
MYADM	transfac_pro__M06208	ZNF460 (directAnnotation).
MYADM	tfdimers__MD00085	MYB (directAnnotation).
MYADM	tfdimers__MD00277	HOXD10 (directAnnotation).
MYADM	metacluster_168.4	ZNF652 (directAnnotation).
MYADM	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
MYADM	swissregulon__hs__KLF6	KLF6 (directAnnotation).
MYADM	metacluster_3.4	SP1; SP2; SP2; SP3 (directAnnotation).
MYADM	taipale_tf_pairs__CUX1_TBX3_AGGTGTGNNNNATCRAT_CAP_repr	CUX1; TBX3 (directAnnotation).
MYADM	dbtfbs__ZFP91_K562_ENCSR898XMH_merged_N1	ZFP91 (directAnnotation).
MYADM	transfac_pro__M05896	ZNF713 (directAnnotation).
MYADM	jaspar__MA1633.2	BACH1 (directAnnotation).
MYADM	jaspar__MA1956.1	FOXO1 (directAnnotation).
MYADM	jaspar__MA1954.1	FOXO1 (directAnnotation).
MYADM	jaspar__MA1946.1	FOXI1 (directAnnotation).
MYADM	tfdimers__MD00221	FOXG1; FOXO1; GABPA (directAnnotation).
MYADM	jaspar__MA1955.1	FOXO1 (directAnnotation).
MYADM	transfac_pro__M01660	GABPA (directAnnotation).
MYADM	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).
MYADM	metacluster_29.2	BCL6; IRF3; IRF3; STAT1; STAT1; STAT1; STAT2; STAT3; STAT3; STAT3; STAT4; STAT4; STAT5A; STAT5A; STAT5A; STAT5A; STAT5B; STAT5B; STAT5B; STAT6 (directAnnotation). STAT3; STAT5A; STAT5A; STAT5A; STAT5A; STAT5A; STAT5B; STAT5B; STAT6; STAT6 (inferredBy_Orthology).
MYADM	jaspar__MA1625.1	STAT5B (inferredBy_Orthology).
MYADM	swissregulon__hs__FOXD3	FOXD3 (directAnnotation).
MYADM	tfdimers__MD00018	ELF1; ELF2; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV4; ETV6; ETV7; FLI1; GABPA; GABPB1; SPI1; SPIB; TAF6; TBP (directAnnotation).
MYADM	cisbp__M00199	SOX17 (inferredBy_Orthology).
MYADM	tfdimers__MD00550	PITX3; TEAD1 (directAnnotation).
MYADM	metacluster_150.4	SKOR1; SKOR1; SKOR2; SKOR2 (directAnnotation).
MYADM	transfac_pro__M06902	ZNF611 (directAnnotation).
MYADM	metacluster_9.3	PAX4 (directAnnotation).
MYADM	cisbp__M00540	PAX6 (inferredBy_Orthology).
MYADM	metacluster_184.45	ALX1 (inferredBy_Orthology).
MYADM	metacluster_135.7	ERG; ERG; ERG; ERG; ERG; ERG; ERG; ETV3; ETV3; FLI1; FLI1; FLI1; FLI1; FLI1; FLI1 (directAnnotation).
MYADM	transfac_pro__M05423	RREB1 (directAnnotation).
MYADM	metacluster_9.21	VSX1 (directAnnotation).
MYADM	metacluster_42.4	LHX3; LHX3; LHX3; LMX1B; PAX6; PBX4 (directAnnotation). DBX1; DBX2; LHX4; NKX2-6; NKX2-8; SATB1; SATB2; SEBOX (inferredBy_Orthology).
MYADM	transfac_pro__M06795	ZNF780B (directAnnotation).
MYADM	metacluster_9.53	LHX3 (directAnnotation).
MYADM	transfac_pro__M06231	ZNF273 (directAnnotation).
MYADM	taipale_tf_pairs__POU2F1_DLX2_WTWTGCATANNTAATTA_CAP_repr	DLX2; POU2F1 (directAnnotation).
MYADM	metacluster_51.39	HOXB8 (directAnnotation).
MYADM	metacluster_9.24	ALX1 (directAnnotation).
MYADM	metacluster_9.25	UNCX (directAnnotation).
MYADM	transfac_pro__M06894	ZFP90 (inferredBy_Orthology).
MYADM	transfac_pro__M02096	PDX1 (directAnnotation).
MYADM	transfac_pro__M06773	ZNF490 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."